|
시장보고서
상품코드
2007980
인크레틴 유사약 시장 : 브랜드별, 약제별, 투여 경로별, 유형별, 연령층별, 성별, 적응증별, 유통 채널별, 지역별Incretin Mimetics Drugs Market, By Brand, By Drug, By Route of Administration, By Type, By Age Group, By Gender, By Indication, By Distribution Channel, By Geography |
||||||
인크레틴 유사약 시장은 2026년에 598억 8,300만 달러로 추정되고 있으며, 2033년까지 1,024억 4,480만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 11.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 598억 8,300만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 11.60% | 2033년 시장 규모 예측 : | 1,024억 4,480만 달러 |
세계의 인크레틴 유사약 시장은 당뇨병 관리 및 관련 대사성 질환에 대한 혁신적인 치료 솔루션에 초점을 맞추고 있는 제약 산업에서 빠르게 진화하고 있는 분야입니다.
인크레틴 유사체(GLP-1 수용체 작용제 및 DPP-4 억제제라고도 함)는 장에서 자연적으로 생성되는 인크레틴 호르몬의 작용을 모방한 항당뇨병약의 일종입니다. 이 약물은 혈당 의존적으로 인슐린 분비를 자극하고, 글루카곤의 방출을 억제하고, 위 내용물의 배출을 지연시키고, 포만감을 촉진하여 포괄적인 혈당 조절을 제공합니다. 이 시장에는 주사제 및 내복약을 포함한 다양한 제형이 포함되어 있으며, 주요 기업은 효능과 환자의 복약 순응도를 향상시키기 위해 연구개발에 많은 투자를 하고 있습니다.
장기지속형 제제 및 병용요법의 도입, 그리고 당뇨병 관리를 넘어 심혈관 보호, 체중 관리 등 적응증 확대로 치료 환경이 크게 발전하고 있습니다. 전 세계 의료 시스템이 제2형 당뇨병과 비만 유병률 증가에 직면한 가운데, 인크레틴 유사체는 기존 항당뇨병제 대비 우수한 임상 결과를 보이는 핵심 치료제로 부상하고 있습니다. 시장 성장 궤적은 질병 부담 증가, 당뇨병 합병증에 대한 인식 증가, 약물전달 시스템의 기술 발전, 신흥 국가의 의료 인프라 확충에 힘입어 성장세를 이어가고 있습니다.
시장 역학
세계의 인크레틴 유사약 시장은 주로 전 세계 제 2형 당뇨병 유병률의 급격한 증가에 의해 주도되고 있습니다. 국제당뇨병연맹(IDF)의 추산에 따르면 전 세계에서 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있으며, 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 인크레틴미메틱스의 우수한 효능 프로파일, 즉 저혈당 위험을 최소화하면서 지속적인 혈당 조절을 제공하는 능력과 체중 감소 및 심혈관 보호와 같은 기타 혜택으로 인해 의료진들 사이에서 선호되는 치료 옵션으로 자리매김하고 있습니다. 의료진들 사이에서 선호되는 치료 옵션으로 자리매김하고 있습니다. 고령 인구의 증가, 좌식 생활습관, 비만율 증가, 의료비 증가는 시장 확대를 더욱 촉진하고 있습니다.
또한 주 1회 주사제, 경구제 등 지속적인 제형 혁신을 통해 환자의 복약 순응도와 치료 결과를 개선하고 있습니다. 그러나 시장에는 기존 항당뇨병제 대비 높은 치료비 등 심각한 제약이 존재하며, 특히 가격에 민감한 시장과 개발도상국에서는 접근성이 제한되어 있습니다. 블록버스터 의약품의 특허만료와 이에 따른 바이오시밀러와의 경쟁은 제약사들에게 가격 압박을 가하고 있습니다. 전임상 시험에서 확인된 위장 장애, 췌장염 위험, 갑상선 종양 발생 등 잠재적 부작용으로 인해 처방 의사들의 망설임과 규제 당국의 정밀한 조사가 이루어지고 있습니다.
그럼에도 불구하고 비만 관리 및 신경 퇴행성 질환에 대한 잠재적 적용 등 당뇨병 이외의 적응증 확대를 통해 큰 기회가 존재합니다. 아시아태평양, 라틴아메리카, 아프리카의 신흥 시장은 의료 인프라의 개선과 당뇨병에 대한 인식이 높아짐에 따라 아직 개발되지 않은 잠재력을 가지고 있습니다. 병용요법 개발, 맞춤형 의료 접근법, 디지털 헬스와의 통합은 시장 진입 기업에게 더 많은 성장 기회를 제공할 것입니다.
본 조사의 주요 특징.
- 이 보고서는 세계 인크레틴 유사 약물 시장에 대한 상세한 분석을 제공하며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모와 CAGR(%)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계의 인크레틴 유사약 시장의 주요 업체를 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 인크레틴 유사약 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 인크레틴 유사약 시장 : 브랜드별, 2021-2033년
제5장 세계의 인크레틴 유사약 시장 : 약제별, 2021-2033년
제6장 세계의 인크레틴 유사약 시장 : 투여 경로별, 2021-2033년
제7장 세계의 인크레틴 유사약 시장 : 유형별, 2021-2033년
제8장 세계의 인크레틴 유사약 시장 : 연령층별, 2021-2033년
제9장 세계의 인크레틴 유사약 시장 : 성별, 2021-2033년
제10장 세계의 인크레틴 유사약 시장 : 적응증별, 2021-2033년
제11장 세계의 인크레틴 유사약 시장 : 유통 채널별, 2021-2033년
제12장 세계의 인크레틴 유사약 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 추천
제15장 참고 문헌 및 조사 방법
KSA 26.04.29Incretin Mimetics Drugs Market is estimated to be valued at USD 59,883.0 Mn in 2026 and is expected to reach USD 102,444.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 59,883.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.60% | 2033 Value Projection: | USD 102,444.8 Mn |
The global incretin mimetics drugs market represents a rapidly evolving segment within the pharmaceutical industry, focusing on innovative therapeutic solutions for diabetes management and related metabolic disorders.
Incretin mimetics, also known as GLP-1 receptor agonists and DPP-4 inhibitors, are a class of antidiabetic medications that mimic the action of incretin hormones naturally produced in the intestine. These drugs work by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety, thereby providing comprehensive glycemic control. The market encompasses various drug formulations including injectable and oral medications, with leading pharmaceutical companies investing heavily in research and development to enhance efficacy and patient compliance.
The therapeutic landscape has witnessed significant advancement with the introduction of long-acting formulations, combination therapies, and expanded indications beyond diabetes management, including cardiovascular protection and weight management. As healthcare systems worldwide grapple with the rising prevalence of type 2 diabetes and obesity, incretin mimetics have emerged as cornerstone treatments offering superior clinical outcomes compared to traditional antidiabetic agents. The market's growth trajectory is supported by increasing disease burden, growing awareness about diabetes complications, technological advancements in drug delivery systems, and expanding healthcare infrastructure in emerging economies.
Market Dynamics
The global incretin mimetics drugs market is primarily driven by the escalating prevalence of type 2 diabetes mellitus worldwide, with the International Diabetes Federation estimating over 537 million adults living with diabetes globally, creating substantial demand for effective therapeutic interventions. The superior efficacy profile of incretin mimetics, including their ability to provide sustained glycemic control with minimal hypoglycemic risk and additional benefits such as weight reduction and cardiovascular protection, has positioned these drugs as preferred treatment options among healthcare providers. Growing geriatric population, sedentary lifestyles, rising obesity rates, and increasing healthcare expenditure further propel market expansion.
Additionally, continuous innovation in drug formulations, including once-weekly injectable options and oral alternatives, enhances patient adherence and treatment outcomes. However, the market faces significant restraints including high treatment costs compared to conventional antidiabetic medications, limiting accessibility particularly in price-sensitive markets and developing regions. Patent expirations of blockbuster drugs and subsequent biosimilar competition pose pricing pressures on manufacturers. Potential side effects such as gastrointestinal disturbances, pancreatitis risks, and rare cases of thyroid tumors in preclinical studies create prescriber hesitancy and regulatory scrutiny.
Nevertheless, substantial opportunities exist through expanding indications beyond diabetes, including obesity management and potential applications in neurodegenerative diseases. Emerging markets in Asia Pacific, Latin America, and Africa present untapped potential due to improving healthcare infrastructure and rising diabetes awareness. The development of combination therapies, personalized medicine approaches, and digital health integration offer additional growth avenues for market participants.
Key Features of the Study
- This report provides in-depth analysis of the global incretin mimetics drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global incretin mimetics drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, AstraZeneca, Sanofi, Boehringer Ingelheim, Amgen, Roche, Genentech, Zealand Pharma, Pfizer, Viking Therapeutics, Structure Therapeutics, Innovent Biologics, Hanmi Pharmaceutical, and Eccogene
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global incretin mimetics drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global incretin mimetics drugs market
Market Segmentation
- Brand Insights (Revenue, USD Mn, 2021 - 2033)
- Ozempic (semaglutide)
- Trulicity Pen (dulaglutide)
- Wegovy (semaglutide)
- Saxenda (Liraglutide)
- Victoza (Liraglutide)
- Rybelsus (semaglutide)
- Zepbound (Tirzepatide)
- Mounjaro (Tirzepatide)
- BYDUREON Bcise (exenatide)
- Others (Januvia and Janumet, etc.) (Sitagliptin)
- Drug Insights (Revenue, USD Mn, 2021 - 2033)
- Semaglutide
- Tirzepatide
- Dulaglutide
- Exenatide
- Liraglutide
- Others
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Subcutaneous
- Oral
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Branded
- Generic
- Age Group Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric/Children
- Adult
- Gender Insights (Revenue, USD Mn, 2021 - 2033)
- Male
- Female
- Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Type 2 Diabetes Mellitus (T2DM)
- Weight Management (Obesity/Overweight)
- Cardiovascular Risk Reduction
- Others
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- Amgen
- Roche
- Genentech
- Zealand Pharma
- Pfizer
- Viking Therapeutics
- Structure Therapeutics
- Innovent Biologics
- Hanmi Pharmaceutical
- Eccogene
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Incretin Mimetics Drugs Market, By Brand
- Global Incretin Mimetics Drugs Market, By Drug
- Global Incretin Mimetics Drugs Market, By Route of Administration
- Global Incretin Mimetics Drugs Market, By Type
- Global Incretin Mimetics Drugs Market, By Age Group
- Global Incretin Mimetics Drugs Market, By Gender
- Global Incretin Mimetics Drugs Market, By Indication
- Global Incretin Mimetics Drugs Market, By Distribution Channel
- Global Incretin Mimetics Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Incretin Mimetics Drugs Market, By Brand, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ozempic (semaglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Trulicity Pen (dulaglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Wegovy (semaglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Saxenda (Liraglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Victoza (Liraglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Rybelsus (semaglutide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Zepbound (Tirzepatide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Mounjaro (Tirzepatide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- BYDUREON Bcise (exenatide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Januvia and Janumet, etc.) (Sitagliptin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Incretin Mimetics Drugs Market, By Drug, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tirzepatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Incretin Mimetics Drugs Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Incretin Mimetics Drugs Market, By Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Incretin Mimetics Drugs Market, By Age Group, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric/Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Incretin Mimetics Drugs Market, By Gender, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Incretin Mimetics Drugs Market, By Indication, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Type 2 Diabetes Mellitus (T2DM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Weight Management (Obesity/Overweight)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Cardiovascular Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Global Incretin Mimetics Drugs Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
12. Global Incretin Mimetics Drugs Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zealand Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viking Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Structure Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Innovent Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hanmi Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eccogene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
